Phase 3 Lung Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are fully active or have only minor restrictions in daily physical activity (as measured by a standard oncology scale called ECOG, with a score of 0 or 1).
- People who have been diagnosed through a tissue or cell sample with a specific type of lung cancer called non-small cell lung cancer (NSCLC), at a stage between Stage II and Stage IIIB, of either squamous or non-squamous type.
- People whose lung cancer was completely removed through surgery.
- People who previously received a type of immunotherapy drug (pembrolizumab or nivolumab) combined with chemotherapy before their surgery.
- People who are enrolled into the trial within 12 weeks of their surgery date.
- People who have no signs of cancer returning or spreading after surgery.
- People whose cancer has been confirmed to have a specific genetic change called a KRAS G12C mutation.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer showed a complete pathological response (meaning no cancer cells were found in the removed tissue) after receiving treatment before surgery.
- People who have previously received a KRAS inhibitor or any other cancer treatment not specified in the trial's plan.
- People who have previously had radiation therapy for their lung cancer, except for limited radiation used to manage symptoms before surgery.
- People who experienced a severe immune-related side effect (Grade 3 or higher) during prior immunotherapy that has since resolved, or a moderate immune-related side effect (Grade 2 or higher) that has not yet resolved.
- People with a currently active autoimmune disease, a history of autoimmune disease, or a condition that weakens the immune system.
- People with serious heart or blood vessel disease.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S. only)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Disease-free Survival (DFS), as Determined by the Investigator
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.